…
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Compugen Ltd. is a clinical-stage biopharmaceutical firm that uses computational target discovery to develop immuno-oncology therapeutics. Long-term growth may be driven by clinical advancement of its pipeline, validation of novel targets from its discovery platform, and licensing or partnership opportunities, which could appeal to investors seeking exposure to emerging oncology biologics.
Principal risks include clinical and regulatory failure, substantial funding needs with potential shareholder dilution, and strong competition in immuno-oncology.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 35.40M | -9.71M | -9.78M | -33.64M | -34.20M |
| Net income | 35.34M | -14.23M | -18.75M | -33.69M | -32.87M |
| Selling general administrative | 9.43M | 9.44M | 9.73M | 10.32M | 10.86M |
| Selling and marketing expenses | - | 0.58M | 0.24M | 0.93M | 0.84M |
| Gross profit | 63.51M | 19.93M | 31.45M | 6.53M | 5.32M |
| Reconciled depreciation | 0.47M | 0.49M | 0.48M | 0.48M | 0.46M |
| Ebit | 31.33M | -14.89M | -12.99M | -35.86M | -35.53M |
| Ebitda | 31.80M | -14.40M | -12.52M | -35.37M | -35.07M |
| Depreciation and amortization | 0.47M | 0.49M | 0.48M | 0.48M | 0.46M |
| Operating income | 31.33M | -14.89M | -12.99M | -35.37M | -35.07M |
| Other operating expenses | 41.44M | 42.76M | 46.45M | 42.87M | 41.07M |
| Interest expense | - | 0.03M | 0.03M | 0.03M | 0.87M |
| Tax provision | 0.05M | 4.52M | 8.97M | 0.06M | 0.00M |
| Interest income | 3.90M | 3.49M | 2.96M | 1.74M | 0.89M |
| Net interest income | 4.38M | 5.20M | 3.21M | 1.74M | 0.87M |
| Income tax expense | 0.05M | 4.52M | 8.97M | 0.06M | -1.33M |
| Total revenue | 72.76M | 27.86M | 33.46M | 7.50M | 6.00M |
| Total operating expenses | 32.19M | 34.83M | 44.45M | 41.90M | 40.39M |
| Cost of revenue | 9.25M | 7.93M | 2.00M | 0.97M | 0.68M |
| Total other income expense net | 4.07M | 5.18M | 3.21M | 1.74M | 0.87M |
| Net income from continuing ops | 35.34M | -14.23M | -18.75M | -33.69M | -34.20M |
| Net income applicable to common shares | - | - | - | -33.69M | -34.20M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 156.87M | 115.00M | 121.33M | 94.18M | 132.16M |
| Other current assets | 2.09M | 2.47M | 2.21M | 72.65M | 109.96M |
| Total liab | 54.14M | 60.08M | 55.77M | 16.50M | 25.47M |
| Total stockholder equity | 102.73M | 54.91M | 65.56M | 77.68M | 106.69M |
| Other current liab | 8.73M | 8.24M | 10.98M | 9.53M | 11.71M |
| Common stock | 0.26M | 0.25M | 0.25M | 0.24M | 0.24M |
| Capital stock | 0.26M | 0.25M | 0.25M | 0.24M | 0.24M |
| Retained earnings | -453.42M | -488.76M | -474.53M | -455.77M | -422.08M |
| Other liab | - | - | - | 3.27M | 6.39M |
| Other assets | - | - | - | 4.69M | 5.04M |
| Cash | 90.60M | 18.23M | 14.26M | 11.06M | 7.80M |
| Total current liabilities | 22.57M | 20.16M | 26.27M | 11.92M | 17.10M |
| Current deferred revenue | 10.97M | 9.63M | 11.15M | - | - |
| Net debt | -87.64M | -15.32M | -12.90M | -9.13M | -5.05M |
| Short term debt | 0.52M | 0.45M | 0.63M | 0.61M | 0.77M |
| Short long term debt total | 2.96M | 2.91M | 1.35M | 1.93M | 2.75M |
| Other stockholder equity | 555.88M | 543.41M | 539.84M | 533.21M | 528.53M |
| Property plant equipment | - | - | - | 3.36M | 3.90M |
| Total current assets | 148.02M | 106.00M | 114.58M | 86.12M | 123.22M |
| Net tangible assets | - | - | - | 77.68M | 106.69M |
| Short term investments | 55.04M | 85.03M | 36.80M | 72.29M | 109.25M |
| Net receivables | 0.29M | 0.27M | 61.32M | 2.42M | 5.46M |
| Inventory | - | - | - | -72.65M | -109.96M |
| Accounts payable | 2.35M | 1.84M | 3.50M | 1.77M | 4.62M |
| Accumulated other comprehensive income | 0.01M | 0.01M | 0.00M | - | - |
| Non currrent assets other | 4.94M | 5.30M | 4.21M | 4.69M | 5.04M |
| Non current assets total | 8.85M | 9.00M | 6.75M | 8.05M | 8.94M |
| Capital lease obligations | 2.96M | 2.91M | 1.35M | 1.93M | 2.75M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 30.32M | -46.25M | 35.51M | 37.06M | 6.91M |
| Change to liabilities | - | - | - | -1.60M | 3.37M |
| Total cashflows from investing activities | 30.00M | -46.25M | 35.51M | 37.06M | 6.62M |
| Total cash from financing activities | 10.60M | 0.55M | 3.08M | 0.35M | 16.84M |
| Change to operating activities | - | - | - | -3.95M | 1.45M |
| Net income | 35.34M | -14.23M | -18.75M | -33.69M | -34.20M |
| Change in cash | 72.37M | 3.97M | 2.83M | 2.91M | 0.70M |
| Begin period cash flow | 18.23M | 14.26M | 11.42M | 8.51M | 7.81M |
| End period cash flow | 90.60M | 18.23M | 14.26M | 11.42M | 8.51M |
| Total cash from operating activities | 31.63M | 49.60M | -35.89M | -34.51M | -22.75M |
| Issuance of capital stock | 10.54M | 0.54M | 3.08M | 0.00M | 14.96M |
| Depreciation | 0.47M | 0.49M | 0.48M | 0.48M | 0.46M |
| Other cashflows from investing activities | - | -0.33M | - | -0.01M | -0.01M |
| Change to inventory | - | - | - | - | -3.37M |
| Change to account receivables | 0.36M | 59.93M | -61.11M | 3.04M | 2.00M |
| Other cashflows from financing activities | -0.00M | 0.01M | 35.51M | 0.35M | 1.88M |
| Change to netincome | - | - | - | 4.26M | 4.17M |
| Capital expenditures | 0.31M | 0.12M | 0.17M | 0.49M | 0.29M |
| Change in working capital | -5.35M | 62.05M | -20.71M | -5.55M | 6.82M |
| Stock based compensation | 1.88M | 3.02M | 3.55M | 4.33M | 4.28M |
| Other non cash items | 1.16M | -1.72M | -0.45M | -0.07M | -0.10M |
| Free cash flow | 31.33M | 49.49M | -36.06M | -34.99M | -23.04M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CGEN Compugen |
-0.06 2.72% |
1.97 | 7.47 | 12.36 | 3.71 | 2.64 | 1.74 | 3.98 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
| Name | Title | Year Born |
|---|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | CEO, Pres & Director | 1967 |
| Dr. Oliver Froescheis Ph.D. | Sr. VP of Corp. & Bus. Devel. | 1966 |
| Dr. Zurit Levine | Sr. VP of Technology Innovation | 1968 |
| Dr. Henry Adewoye M.D. | Sr. VP & Chief Medical Officer | 1965 |
| Mr. Alberto Sessa | Chief Financial Officer | 1962 |
| Ms. Yvonne Naughton | Head of Investor Relations & Corp. Communications | NA |
| Mr. Eran Ben Dor | Gen. Counsel & Corp. Sec. | NA |
| Ms. Dorit Amitay | VP of HR | 1968 |
| Dr. Yaron Turpaz M.B.A., Ph.D., MBA | Sr. VP & Sr. Advisor of Computational Discovery | 1971 |
| Rivka Schwartz | VP Research and Discovery | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.